Bvf INC Position In Immune Design Corp (IMDZ) Was Has Raised

July 12, 2018 - By Margaret Downey

Investors sentiment decreased to 1.57 in 2018 Q1. Its down 0.35, from 1.92 in 2017Q4. It dived, as 11 investors sold IMDZ shares while 12 reduced holdings. 10 funds opened positions while 26 raised stakes. 21.61 million shares or 6.41% less from 23.09 million shares in 2017Q4 were reported. Deutsche Fincl Bank Ag, a Germany-based fund reported 34,256 shares. Proquest Assocs Iv Limited Co holds 4.69% in Immune Design Corp. (NASDAQ:IMDZ) or 1.24 million shares. Alabama-based Weiss Multi has invested 0.01% in Immune Design Corp. (NASDAQ:IMDZ). 35,010 are held by Price T Rowe Associate Md. Morgan Stanley invested 0% in Immune Design Corp. (NASDAQ:IMDZ). Balyasny Asset Management Limited Liability Company reported 60,812 shares. California State Teachers Retirement holds 50,518 shares. Crow Point Ptnrs Llc reported 0% in Immune Design Corp. (NASDAQ:IMDZ). 3,233 are held by Royal Bancorporation Of Canada. Rhumbline Advisers reported 25,863 shares. 250 were reported by Thompson Davis Communications. Personal Advisors Corp accumulated 24,000 shares or 0% of the stock. Jpmorgan Chase And holds 842,927 shares. Drw Secs Limited Liability Corp owns 37,000 shares or 0.01% of their US portfolio. Bridgeway Cap Incorporated has invested 0.01% in Immune Design Corp. (NASDAQ:IMDZ).

Bvf Inc increased its stake in Immune Design Corp (IMDZ) by 179.37% based on its latest 2018Q1 regulatory filing with the SEC. Bvf Inc bought 2.64M shares as the company’s stock rose 30.77% while stock markets declined. The hedge fund held 4.11M shares of the major pharmaceuticals company at the end of 2018Q1, valued at $13.55 million, up from 1.47M at the end of the previous reported quarter. Bvf Inc who had been investing in Immune Design Corp for a number of months, seems to be bullish on the $231.00 million market cap company. The stock increased 1.05% or $0.05 during the last trading session, reaching $4.8. About 28,181 shares traded. Immune Design Corp. (NASDAQ:IMDZ) has declined 47.53% since July 12, 2017 and is downtrending. It has underperformed by 60.10% the S&P500.

Bvf Inc, which manages about $999.89M and $986.48M US Long portfolio, decreased its stake in Array Biopharma Inc (NASDAQ:ARRY) by 3.62 million shares to 5.06 million shares, valued at $82.62 million in 2018Q1, according to the filing. It also reduced its holding in Xenon Pharmaceuticals Inc by 2.87M shares in the quarter, leaving it with 720,830 shares, and cut its stake in Blueprint Medicines Corp.

Another recent and important Immune Design Corp. (NASDAQ:IMDZ) news was published by Globenewswire.com which published an article titled: “Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the …” on June 25, 2018.

Immune Design Corp. (NASDAQ:IMDZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: